The experience of more than 30 years of treatment shows that Parkinson’s disease is not curable and requires lifelong medication, and is prone to uncontrollable long-term side effects after 2-5 years of levodopa treatment, so the use of drugs needs to be rationalized to make the efficacy of each drug last as long as possible while reducing the chance of side effects. The use of medications needs to be rationalized to maximize the duration of efficacy of each drug and minimize the chance of side effects. Not every patient with a recent diagnosis of Parkinson’s disease needs to start levodopa therapy immediately. The general course of Parkinson’s disease can be divided into a compensated phase and a decompensated phase. In the compensated phase, the patient’s symptoms are milder and the patient can maintain a normal daily life and even work, so rehabilitation exercises, physical therapy, hydrotherapy and massage can be performed. Neuroprotective treatment, such as Silegiline, can also be considered. In the decompensated phase or when functional impairment occurs, symptomatic treatment is needed to improve the patient’s quality of life and ability to work. The following phenomena should be considered as functional impairment and require symptomatic treatment: 1. symptoms affecting the dominant hand; 2. symptoms affecting employment or work ability; 3. significant hypokinetic symptoms, gait disorders, and postural disorders; 4. patient’s views and requirements. There are many kinds of medications for symptomatic treatment, including dopamine receptor agonists, levodopa, amantadine, etc. Many studies have demonstrated that dopamine receptor agonists may have neuroprotective effects. Many clinical trials have also demonstrated that the use of dopamine agonists first and the addition of levodopa when the efficacy wanes can significantly reduce the long-term side effects of levodopa, therefore, it is currently advocated to treat with dopamine agonists first and then add levodopa when the efficacy wanes, if conditions permit. If the patient is 65-70 years of age or older at the time of diagnosis of Parkinson’s disease, treatment with levodopa may also be considered at the outset.